British drugmaker AstraZeneca warned on Thursday of higher costs in 2013 as it invests through a slump in sales caused by a wave of patent expiries for key medicines.

Sales in the second quarter fell by a slightly greater-than-expected 6 percent to $6.23 billion, while earnings tumbled by nearly a quarter due to a higher tax rate.

Reuters